Cloning	Cloning	NN	B-NP	O		0	7
,	,	,	O	O		7	8
expression	expression	NN	B-NP	O		9	19
,	,	,	O	O		19	20
purification	purification	NN	B-NP	O		21	33
,	,	,	O	O		33	34
crystallization	crystallization	NN	B-NP	O		35	50
and	and	CC	O	O		51	54
X-ray	X-ray	NN	B-NP	O		55	60
crystallographic	crystallographic	JJ	I-NP	O		61	77
analysis	analysis	NN	I-NP	O		78	86
of	of	IN	B-PP	O		87	89
Rv3168	Rv3168	NN	B-NP	O		90	96
from	from	IN	B-PP	O		97	101
Mycobacterium tuberculosis H37Rv	Mycobacterium_tuberculosis_H37Rv	NN	B-NP	O		102	134
.	.	.	O	O		134	135

Tuberculosis	Tuberculosis	NN	B-NP	O		136	148
is	be	VBZ	B-VP	O		149	151
a	a	DT	B-NP	O		152	153
widespread	widespread	JJ	I-NP	O		154	164
and	and	CC	I-NP	O		165	168
deadly	deadly	JJ	I-NP	O		169	175
infectious	infectious	JJ	I-NP	O		176	186
disease	disease	NN	I-NP	O		187	194
,	,	,	O	O		194	195
with	with	IN	B-PP	O		196	200
one	one	CD	B-NP	O		201	204
third	third	NN	I-NP	O		205	210
of	of	IN	B-PP	O		211	213
the	the	DT	B-NP	O		214	217
human	human	JJ	I-NP	O		218	223
population	population	NN	I-NP	O		224	234
already	already	RB	B-VP	O		235	242
being	be	VBG	I-VP	O		243	248
infected	infect	VBN	I-VP	O		249	257
.	.	.	O	O		257	258

Aminoglycoside	Aminoglycoside	NN	B-NP	O		259	273
antibiotics	antibiotic	NNS	I-NP	O		274	285
have	have	VBP	B-VP	O		286	290
become	become	VBN	I-VP	O		291	297
less	less	RBR	B-ADJP	O		298	302
effective	effective	JJ	I-ADJP	O		303	312
in	in	IN	B-PP	O		313	315
recent	recent	JJ	B-NP	O		316	322
years	year	NNS	I-NP	O		323	328
owing	owe	VBG	B-VP	O		329	334
to	to	TO	B-PP	O		335	337
antibiotic	antibiotic	JJ	B-NP	O		338	348
resistance	resistance	NN	I-NP	O		349	359
,	,	,	O	O		359	360
which	which	WDT	B-NP	O		361	366
arises	arise	VBZ	B-VP	O		367	373
primarily	primarily	RB	B-ADVP	O		374	383
through	through	IN	B-PP	O		384	391
enzymatic	enzymatic	JJ	B-NP	O		392	401
modification	modification	NN	I-NP	O		402	414
of	of	IN	B-PP	O		415	417
the	the	DT	B-NP	O		418	421
antibiotics	antibiotic	NNS	I-NP	O		422	433
.	.	.	O	O		433	434

The	The	DT	B-NP	O		435	438
gene	gene	NN	I-NP	O		439	443
product	product	NN	I-NP	O		444	451
Rv3168	Rv3168	NN	I-NP	O		452	458
,	,	,	O	O		458	459
a	a	DT	B-NP	O		460	461
putative	putative	JJ	I-NP	O		462	470
aminoglycoside	aminoglycoside	NN	I-NP	O		471	485
phosphotransferase	phosphotransferase	NN	I-NP	O		486	504
(	(	(	O	O		505	506
APH	APH	NN	B-NP	O		506	509
)	)	)	O	O		509	510
,	,	,	O	O		510	511
from	from	IN	B-PP	O		512	516
Mycobacterium tuberculosis	Mycobacterium_tuberculosis	NN	B-NP	O		517	543
was	be	VBD	B-VP	O		544	547
crystallized	crystallize	VBN	I-VP	O		548	560
using	use	VBG	I-VP	O		561	566
the	the	DT	B-NP	O		567	570
sitting	sit	VBG	I-NP	O		571	578
-	-	HYPH	I-NP	O		578	579
drop	drop	NN	I-NP	O		579	583
vapour	vapour	NN	I-NP	O		584	590
-	-	HYPH	B-NP	O		590	591
diffusion	diffusion	NN	I-NP	O		591	600
method	method	NN	I-NP	O		601	607
in	in	IN	B-PP	O		608	610
the	the	DT	B-NP	O		611	614
presence	presence	NN	I-NP	O		615	623
of	of	IN	B-PP	O		624	626
0.2	0.2	CD	B-NP	O		627	630
M	M	NN	I-NP	O		631	632
calcium	calcium	NN	I-NP	O		633	640
acetate	acetate	NN	I-NP	O		641	648
,	,	,	O	O		648	649
0.1	0.1	CD	B-NP	O		650	653
M	M	NN	I-NP	O		654	655
Tris	Tris	NN	I-NP	O		656	660
-	-	HYPH	B-NP	O		660	661
HCl	HCl	NN	I-NP	O		661	664
pH	pH	NN	I-NP	O		665	667
7.0	7.0	CD	B-NP	O		668	671
and	and	CC	I-NP	O		672	675
20%	20%	CD	I-NP	O		676	679
PEG	PEG	NN	I-NP	O		680	683
3000	3000	CD	I-NP	O		684	688
at	at	IN	B-PP	O		689	691
295	295	CD	B-NP	O		692	695
K	K	NN	I-NP	O		696	697
.	.	.	O	O		697	698

X-ray	X-ray	NN	B-NP	O		699	704
diffraction	diffraction	NN	I-NP	O		705	716
data	datum	NNS	I-NP	O		717	721
were	be	VBD	B-VP	O		722	726
collected	collect	VBN	I-VP	O		727	736
to	to	TO	B-PP	O		737	739
a	a	DT	B-NP	O		740	741
maximum	maximum	NN	I-NP	O		742	749
resolution	resolution	NN	I-NP	O		750	760
of	of	IN	B-PP	O		761	763
1.67	1.67	CD	B-NP	O		764	768
Å	Å	NN	I-NP	O		769	770
on	on	IN	B-PP	O		771	773
a	a	DT	B-NP	O		774	775
synchrotron	synchrotron	NN	I-NP	O		776	787
beamline	beamline	NN	I-NP	O		788	796
.	.	.	O	O		796	797

The	The	DT	B-NP	O		798	801
crystal	crystal	NN	I-NP	O		802	809
belonged	belong	VBD	B-VP	O		810	818
to	to	TO	I-VP	O		819	821
space	space	VB	I-VP	O		822	827
group	group	NN	B-NP	O		828	833
P2(1)2(1)2(1)	P2(1)2(1)2(1)	NN	I-NP	O		834	847
,	,	,	O	O		847	848
with	with	IN	B-PP	O		849	853
unit	unit	NN	B-NP	O		854	858
-	-	HYPH	B-NP	O		858	859
cell	cell	NN	I-NP	O		859	863
parameters	parameter	NNS	I-NP	O		864	874
a	a	DT	B-NP	O		875	876
=	=	JJ	I-NP	O		877	878
56.74	56.74	CD	I-NP	O		879	884
,	,	,	O	O		884	885
b	b	NN	B-NP	O		886	887
=	=	SYM	B-VP	O		888	889
62.37	62.37	CD	B-NP	O		890	895
,	,	,	O	O		895	896
c	c	NN	B-NP	O		897	898
=	=	SYM	B-VP	O		899	900
103.61	103.61	CD	B-NP	O		901	907
Å	Å	NN	I-NP	O		908	909
.	.	.	O	O		909	910

With	With	IN	B-PP	O		911	915
one	one	CD	B-NP	O		916	919
molecule	molecule	NN	I-NP	O		920	928
per	per	IN	B-PP	O		929	932
asymmetric	asymmetric	JJ	B-NP	O		933	943
unit	unit	NN	I-NP	O		944	948
,	,	,	O	O		948	949
the	the	DT	B-NP	O		950	953
crystal	crystal	JJ	I-NP	O		954	961
volume	volume	NN	I-NP	O		962	968
per	per	IN	B-PP	O		969	972
unit	unit	NN	B-NP	O		973	977
protein	protein	NN	I-NP	O		978	985
weight	weight	NN	I-NP	O		986	992
(V(M))	(V(M))	NN	I-NP	O		993	999
is	be	VBZ	B-VP	O		1000	1002
2.91	2.91	CD	B-NP	O		1003	1007
Å(3)	Å(3)	NN	I-NP	O		1008	1012
Da	Da	NN	I-NP	O		1013	1015
(	(	(	O	O		1015	1016
-1	-1	CD	B-NP	O		1016	1018
)	)	)	O	O		1018	1019
.	.	.	O	O		1019	1020

The	The	DT	B-NP	O		1021	1024
structure	structure	NN	I-NP	O		1025	1034
was	be	VBD	B-VP	O		1035	1038
solved	solve	VBN	I-VP	O		1039	1045
by	by	IN	B-PP	O		1046	1048
the	the	DT	B-NP	O		1049	1052
single	single	JJ	I-NP	O		1053	1059
-	-	HYPH	I-NP	O		1059	1060
wavelength	wavelength	NN	I-NP	O		1060	1070
anomalous	anomalous	JJ	I-NP	O		1071	1080
dispersion	dispersion	NN	I-NP	O		1081	1091
method	method	NN	I-NP	O		1092	1098
and	and	CC	I-NP	O		1099	1102
refinement	refinement	NN	I-NP	O		1103	1113
of	of	IN	B-PP	O		1114	1116
the	the	DT	B-NP	O		1117	1120
selenomethionine	selenomethionine	NN	I-NP	O		1121	1137
structure	structure	NN	I-NP	O		1138	1147
is	be	VBZ	B-VP	O		1148	1150
in	in	IN	B-PP	O		1151	1153
progress	progress	NN	B-NP	O		1154	1162
.	.	.	O	O		1162	1163

